nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxybutynin—CYP2C8—Tazarotene—psoriasis	0.0895	0.134	CbGbCtD
Oxybutynin—CYP3A5—Beclomethasone—psoriasis	0.0865	0.129	CbGbCtD
Oxybutynin—CYP2D6—Hydroxyurea—psoriasis	0.0402	0.0601	CbGbCtD
Oxybutynin—CYP2C8—Cholecalciferol—psoriasis	0.0382	0.0571	CbGbCtD
Oxybutynin—CYP3A5—Mycophenolate mofetil—psoriasis	0.0345	0.0515	CbGbCtD
Oxybutynin—CYP2C8—Mycophenolate mofetil—psoriasis	0.0331	0.0495	CbGbCtD
Oxybutynin—CYP3A4—Calcitriol—psoriasis	0.0301	0.0449	CbGbCtD
Oxybutynin—CYP3A5—Hydrocortisone—psoriasis	0.0277	0.0413	CbGbCtD
Oxybutynin—CYP2C8—Hydrocortisone—psoriasis	0.0266	0.0397	CbGbCtD
Oxybutynin—CYP3A5—Cyclosporine—psoriasis	0.0261	0.039	CbGbCtD
Oxybutynin—CYP2C8—Cyclosporine—psoriasis	0.0251	0.0375	CbGbCtD
Oxybutynin—CYP2D6—Cholecalciferol—psoriasis	0.0244	0.0364	CbGbCtD
Oxybutynin—CYP3A4—Methoxsalen—psoriasis	0.0234	0.0349	CbGbCtD
Oxybutynin—CYP3A5—Dexamethasone—psoriasis	0.0172	0.0257	CbGbCtD
Oxybutynin—CYP2C8—Dexamethasone—psoriasis	0.0165	0.0247	CbGbCtD
Oxybutynin—CYP2D6—Cyclosporine—psoriasis	0.016	0.0239	CbGbCtD
Oxybutynin—CYP3A4—Cholecalciferol—psoriasis	0.0155	0.0232	CbGbCtD
Oxybutynin—CYP3A4—Mycophenolate mofetil—psoriasis	0.0134	0.0201	CbGbCtD
Oxybutynin—CYP3A4—Triamcinolone—psoriasis	0.0134	0.0201	CbGbCtD
Oxybutynin—CYP3A4—Betamethasone—psoriasis	0.0115	0.0172	CbGbCtD
Oxybutynin—CYP3A4—Prednisolone—psoriasis	0.0114	0.017	CbGbCtD
Oxybutynin—CYP3A4—Hydrocortisone—psoriasis	0.0108	0.0161	CbGbCtD
Oxybutynin—CYP3A4—Prednisone—psoriasis	0.0107	0.016	CbGbCtD
Oxybutynin—CYP2D6—Dexamethasone—psoriasis	0.0105	0.0158	CbGbCtD
Oxybutynin—CYP3A4—Cyclosporine—psoriasis	0.0102	0.0152	CbGbCtD
Oxybutynin—CYP3A4—Dexamethasone—psoriasis	0.00671	0.01	CbGbCtD
Oxybutynin—CYP2C8—CYP2E1 reactions—CYP2S1—psoriasis	0.000297	0.0785	CbGpPWpGaD
Oxybutynin—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.000244	0.0645	CbGpPWpGaD
Oxybutynin—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000228	0.0601	CbGpPWpGaD
Oxybutynin—CYP3A5—Xenobiotics—CYP2S1—psoriasis	0.000213	0.0562	CbGpPWpGaD
Oxybutynin—CYP2C8—Xenobiotics—CYP2S1—psoriasis	0.000184	0.0487	CbGpPWpGaD
Oxybutynin—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000151	0.04	CbGpPWpGaD
Oxybutynin—CYP3A4—Xenobiotics—CYP2S1—psoriasis	9.9e-05	0.0261	CbGpPWpGaD
Oxybutynin—Gastrointestinal pain—Cyclosporine—psoriasis	9.66e-05	0.000296	CcSEcCtD
Oxybutynin—Loss of consciousness—Betamethasone—psoriasis	9.66e-05	0.000296	CcSEcCtD
Oxybutynin—Loss of consciousness—Dexamethasone—psoriasis	9.66e-05	0.000296	CcSEcCtD
Oxybutynin—Dizziness—Mycophenolic acid—psoriasis	9.66e-05	0.000295	CcSEcCtD
Oxybutynin—Epistaxis—Methotrexate—psoriasis	9.65e-05	0.000295	CcSEcCtD
Oxybutynin—Paraesthesia—Prednisolone—psoriasis	9.65e-05	0.000295	CcSEcCtD
Oxybutynin—Tachycardia—Triamcinolone—psoriasis	9.65e-05	0.000295	CcSEcCtD
Oxybutynin—Mental disorder—Prednisone—psoriasis	9.63e-05	0.000295	CcSEcCtD
Oxybutynin—Malnutrition—Prednisone—psoriasis	9.57e-05	0.000293	CcSEcCtD
Oxybutynin—Erythema—Prednisone—psoriasis	9.57e-05	0.000293	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Hydrocortisone—psoriasis	9.57e-05	0.000293	CcSEcCtD
Oxybutynin—Convulsion—Dexamethasone—psoriasis	9.52e-05	0.000291	CcSEcCtD
Oxybutynin—Convulsion—Betamethasone—psoriasis	9.52e-05	0.000291	CcSEcCtD
Oxybutynin—Feeling abnormal—Mycophenolate mofetil—psoriasis	9.5e-05	0.000291	CcSEcCtD
Oxybutynin—Insomnia—Hydrocortisone—psoriasis	9.5e-05	0.000291	CcSEcCtD
Oxybutynin—Hypertension—Dexamethasone—psoriasis	9.49e-05	0.00029	CcSEcCtD
Oxybutynin—Hypertension—Betamethasone—psoriasis	9.49e-05	0.00029	CcSEcCtD
Oxybutynin—Paraesthesia—Hydrocortisone—psoriasis	9.43e-05	0.000288	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	9.42e-05	0.000288	CcSEcCtD
Oxybutynin—Urticaria—Cyclosporine—psoriasis	9.38e-05	0.000287	CcSEcCtD
Oxybutynin—Abdominal pain—Cyclosporine—psoriasis	9.34e-05	0.000286	CcSEcCtD
Oxybutynin—Anxiety—Dexamethasone—psoriasis	9.32e-05	0.000285	CcSEcCtD
Oxybutynin—Anxiety—Betamethasone—psoriasis	9.32e-05	0.000285	CcSEcCtD
Oxybutynin—Vomiting—Mycophenolic acid—psoriasis	9.28e-05	0.000284	CcSEcCtD
Oxybutynin—Discomfort—Betamethasone—psoriasis	9.24e-05	0.000283	CcSEcCtD
Oxybutynin—Discomfort—Dexamethasone—psoriasis	9.24e-05	0.000283	CcSEcCtD
Oxybutynin—Dyspepsia—Hydrocortisone—psoriasis	9.24e-05	0.000283	CcSEcCtD
Oxybutynin—Rash—Mycophenolic acid—psoriasis	9.21e-05	0.000282	CcSEcCtD
Oxybutynin—Dermatitis—Mycophenolic acid—psoriasis	9.2e-05	0.000281	CcSEcCtD
Oxybutynin—Pain—Prednisolone—psoriasis	9.19e-05	0.000281	CcSEcCtD
Oxybutynin—Urticaria—Mycophenolate mofetil—psoriasis	9.16e-05	0.00028	CcSEcCtD
Oxybutynin—Headache—Mycophenolic acid—psoriasis	9.15e-05	0.00028	CcSEcCtD
Oxybutynin—Decreased appetite—Hydrocortisone—psoriasis	9.13e-05	0.000279	CcSEcCtD
Oxybutynin—Pharyngitis—Methotrexate—psoriasis	9.12e-05	0.000279	CcSEcCtD
Oxybutynin—Abdominal pain—Mycophenolate mofetil—psoriasis	9.11e-05	0.000279	CcSEcCtD
Oxybutynin—Urinary tract disorder—Methotrexate—psoriasis	9.07e-05	0.000278	CcSEcCtD
Oxybutynin—Gastrointestinal disorder—Hydrocortisone—psoriasis	9.06e-05	0.000277	CcSEcCtD
Oxybutynin—Fatigue—Hydrocortisone—psoriasis	9.05e-05	0.000277	CcSEcCtD
Oxybutynin—Vision blurred—Prednisone—psoriasis	9.02e-05	0.000276	CcSEcCtD
Oxybutynin—Urethral disorder—Methotrexate—psoriasis	9.01e-05	0.000276	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Triamcinolone—psoriasis	9.01e-05	0.000276	CcSEcCtD
Oxybutynin—Pain—Hydrocortisone—psoriasis	8.98e-05	0.000275	CcSEcCtD
Oxybutynin—Anaphylactic shock—Betamethasone—psoriasis	8.97e-05	0.000274	CcSEcCtD
Oxybutynin—Anaphylactic shock—Dexamethasone—psoriasis	8.97e-05	0.000274	CcSEcCtD
Oxybutynin—Oedema—Betamethasone—psoriasis	8.97e-05	0.000274	CcSEcCtD
Oxybutynin—Oedema—Dexamethasone—psoriasis	8.97e-05	0.000274	CcSEcCtD
Oxybutynin—Insomnia—Triamcinolone—psoriasis	8.94e-05	0.000274	CcSEcCtD
Oxybutynin—Infection—Betamethasone—psoriasis	8.91e-05	0.000273	CcSEcCtD
Oxybutynin—Infection—Dexamethasone—psoriasis	8.91e-05	0.000273	CcSEcCtD
Oxybutynin—Ill-defined disorder—Prednisone—psoriasis	8.88e-05	0.000272	CcSEcCtD
Oxybutynin—Paraesthesia—Triamcinolone—psoriasis	8.88e-05	0.000272	CcSEcCtD
Oxybutynin—Feeling abnormal—Prednisolone—psoriasis	8.86e-05	0.000271	CcSEcCtD
Oxybutynin—Visual impairment—Methotrexate—psoriasis	8.86e-05	0.000271	CcSEcCtD
Oxybutynin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	8.84e-05	0.0233	CbGpPWpGaD
Oxybutynin—Shock—Betamethasone—psoriasis	8.82e-05	0.00027	CcSEcCtD
Oxybutynin—Shock—Dexamethasone—psoriasis	8.82e-05	0.00027	CcSEcCtD
Oxybutynin—Nervous system disorder—Dexamethasone—psoriasis	8.8e-05	0.000269	CcSEcCtD
Oxybutynin—Nervous system disorder—Betamethasone—psoriasis	8.8e-05	0.000269	CcSEcCtD
Oxybutynin—Agitation—Prednisone—psoriasis	8.8e-05	0.000269	CcSEcCtD
Oxybutynin—Tachycardia—Dexamethasone—psoriasis	8.75e-05	0.000268	CcSEcCtD
Oxybutynin—Tachycardia—Betamethasone—psoriasis	8.75e-05	0.000268	CcSEcCtD
Oxybutynin—Angioedema—Prednisone—psoriasis	8.75e-05	0.000268	CcSEcCtD
Oxybutynin—CYP3A5—Oxidation by Cytochrome P450—CYP2S1—psoriasis	8.72e-05	0.023	CbGpPWpGaD
Oxybutynin—Hypersensitivity—Cyclosporine—psoriasis	8.7e-05	0.000266	CcSEcCtD
Oxybutynin—Dyspepsia—Triamcinolone—psoriasis	8.7e-05	0.000266	CcSEcCtD
Oxybutynin—Nausea—Mycophenolic acid—psoriasis	8.67e-05	0.000265	CcSEcCtD
Oxybutynin—Feeling abnormal—Hydrocortisone—psoriasis	8.65e-05	0.000265	CcSEcCtD
Oxybutynin—Malaise—Prednisone—psoriasis	8.63e-05	0.000264	CcSEcCtD
Oxybutynin—Eye disorder—Methotrexate—psoriasis	8.59e-05	0.000263	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Hydrocortisone—psoriasis	8.59e-05	0.000263	CcSEcCtD
Oxybutynin—Syncope—Prednisone—psoriasis	8.58e-05	0.000263	CcSEcCtD
Oxybutynin—Tinnitus—Methotrexate—psoriasis	8.57e-05	0.000262	CcSEcCtD
Oxybutynin—Anorexia—Dexamethasone—psoriasis	8.55e-05	0.000262	CcSEcCtD
Oxybutynin—Anorexia—Betamethasone—psoriasis	8.55e-05	0.000262	CcSEcCtD
Oxybutynin—Urticaria—Prednisolone—psoriasis	8.54e-05	0.000261	CcSEcCtD
Oxybutynin—Cardiac disorder—Methotrexate—psoriasis	8.53e-05	0.000261	CcSEcCtD
Oxybutynin—Fatigue—Triamcinolone—psoriasis	8.52e-05	0.000261	CcSEcCtD
Oxybutynin—Hypersensitivity—Mycophenolate mofetil—psoriasis	8.49e-05	0.00026	CcSEcCtD
Oxybutynin—Asthenia—Cyclosporine—psoriasis	8.48e-05	0.000259	CcSEcCtD
Oxybutynin—Pain—Triamcinolone—psoriasis	8.45e-05	0.000259	CcSEcCtD
Oxybutynin—Loss of consciousness—Prednisone—psoriasis	8.41e-05	0.000257	CcSEcCtD
Oxybutynin—Hypotension—Betamethasone—psoriasis	8.38e-05	0.000256	CcSEcCtD
Oxybutynin—Hypotension—Dexamethasone—psoriasis	8.38e-05	0.000256	CcSEcCtD
Oxybutynin—Pruritus—Cyclosporine—psoriasis	8.36e-05	0.000256	CcSEcCtD
Oxybutynin—Urticaria—Hydrocortisone—psoriasis	8.34e-05	0.000255	CcSEcCtD
Oxybutynin—Angiopathy—Methotrexate—psoriasis	8.34e-05	0.000255	CcSEcCtD
Oxybutynin—Abdominal pain—Hydrocortisone—psoriasis	8.3e-05	0.000254	CcSEcCtD
Oxybutynin—Convulsion—Prednisone—psoriasis	8.29e-05	0.000254	CcSEcCtD
Oxybutynin—Mediastinal disorder—Methotrexate—psoriasis	8.28e-05	0.000253	CcSEcCtD
Oxybutynin—Asthenia—Mycophenolate mofetil—psoriasis	8.27e-05	0.000253	CcSEcCtD
Oxybutynin—Hypertension—Prednisone—psoriasis	8.26e-05	0.000253	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Dexamethasone—psoriasis	8.17e-05	0.00025	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Betamethasone—psoriasis	8.17e-05	0.00025	CcSEcCtD
Oxybutynin—Pruritus—Mycophenolate mofetil—psoriasis	8.15e-05	0.000249	CcSEcCtD
Oxybutynin—Arthralgia—Prednisone—psoriasis	8.15e-05	0.000249	CcSEcCtD
Oxybutynin—Feeling abnormal—Triamcinolone—psoriasis	8.15e-05	0.000249	CcSEcCtD
Oxybutynin—Anxiety—Prednisone—psoriasis	8.12e-05	0.000248	CcSEcCtD
Oxybutynin—Insomnia—Dexamethasone—psoriasis	8.11e-05	0.000248	CcSEcCtD
Oxybutynin—Insomnia—Betamethasone—psoriasis	8.11e-05	0.000248	CcSEcCtD
Oxybutynin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	8.09e-05	0.000248	CcSEcCtD
Oxybutynin—Diarrhoea—Cyclosporine—psoriasis	8.08e-05	0.000247	CcSEcCtD
Oxybutynin—Paraesthesia—Dexamethasone—psoriasis	8.05e-05	0.000246	CcSEcCtD
Oxybutynin—Paraesthesia—Betamethasone—psoriasis	8.05e-05	0.000246	CcSEcCtD
Oxybutynin—Discomfort—Prednisone—psoriasis	8.05e-05	0.000246	CcSEcCtD
Oxybutynin—Mental disorder—Methotrexate—psoriasis	8.05e-05	0.000246	CcSEcCtD
Oxybutynin—Erythema—Methotrexate—psoriasis	8e-05	0.000245	CcSEcCtD
Oxybutynin—Malnutrition—Methotrexate—psoriasis	8e-05	0.000245	CcSEcCtD
Oxybutynin—Hypersensitivity—Prednisolone—psoriasis	7.92e-05	0.000242	CcSEcCtD
Oxybutynin—Dyspepsia—Betamethasone—psoriasis	7.9e-05	0.000242	CcSEcCtD
Oxybutynin—Dyspepsia—Dexamethasone—psoriasis	7.9e-05	0.000242	CcSEcCtD
Oxybutynin—Diarrhoea—Mycophenolate mofetil—psoriasis	7.88e-05	0.000241	CcSEcCtD
Oxybutynin—Urticaria—Triamcinolone—psoriasis	7.85e-05	0.00024	CcSEcCtD
Oxybutynin—Dysgeusia—Methotrexate—psoriasis	7.83e-05	0.00024	CcSEcCtD
Oxybutynin—Dizziness—Cyclosporine—psoriasis	7.81e-05	0.000239	CcSEcCtD
Oxybutynin—Oedema—Prednisone—psoriasis	7.81e-05	0.000239	CcSEcCtD
Oxybutynin—Anaphylactic shock—Prednisone—psoriasis	7.81e-05	0.000239	CcSEcCtD
Oxybutynin—Decreased appetite—Dexamethasone—psoriasis	7.8e-05	0.000239	CcSEcCtD
Oxybutynin—Decreased appetite—Betamethasone—psoriasis	7.8e-05	0.000239	CcSEcCtD
Oxybutynin—Infection—Prednisone—psoriasis	7.76e-05	0.000237	CcSEcCtD
Oxybutynin—Gastrointestinal disorder—Dexamethasone—psoriasis	7.74e-05	0.000237	CcSEcCtD
Oxybutynin—Gastrointestinal disorder—Betamethasone—psoriasis	7.74e-05	0.000237	CcSEcCtD
Oxybutynin—Back pain—Methotrexate—psoriasis	7.74e-05	0.000237	CcSEcCtD
Oxybutynin—Hypersensitivity—Hydrocortisone—psoriasis	7.74e-05	0.000237	CcSEcCtD
Oxybutynin—Fatigue—Dexamethasone—psoriasis	7.73e-05	0.000237	CcSEcCtD
Oxybutynin—Fatigue—Betamethasone—psoriasis	7.73e-05	0.000237	CcSEcCtD
Oxybutynin—Shock—Prednisone—psoriasis	7.69e-05	0.000235	CcSEcCtD
Oxybutynin—Pain—Betamethasone—psoriasis	7.67e-05	0.000235	CcSEcCtD
Oxybutynin—Pain—Dexamethasone—psoriasis	7.67e-05	0.000235	CcSEcCtD
Oxybutynin—Nervous system disorder—Prednisone—psoriasis	7.66e-05	0.000234	CcSEcCtD
Oxybutynin—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	7.66e-05	0.0202	CbGpPWpGaD
Oxybutynin—Tachycardia—Prednisone—psoriasis	7.62e-05	0.000233	CcSEcCtD
Oxybutynin—Dizziness—Mycophenolate mofetil—psoriasis	7.62e-05	0.000233	CcSEcCtD
Oxybutynin—Skin disorder—Prednisone—psoriasis	7.59e-05	0.000232	CcSEcCtD
Oxybutynin—CYP2C8—Oxidation by Cytochrome P450—CYP2S1—psoriasis	7.56e-05	0.02	CbGpPWpGaD
Oxybutynin—Vision blurred—Methotrexate—psoriasis	7.54e-05	0.000231	CcSEcCtD
Oxybutynin—Asthenia—Hydrocortisone—psoriasis	7.53e-05	0.00023	CcSEcCtD
Oxybutynin—Vomiting—Cyclosporine—psoriasis	7.51e-05	0.00023	CcSEcCtD
Oxybutynin—Rash—Cyclosporine—psoriasis	7.45e-05	0.000228	CcSEcCtD
Oxybutynin—Anorexia—Prednisone—psoriasis	7.45e-05	0.000228	CcSEcCtD
Oxybutynin—Dermatitis—Cyclosporine—psoriasis	7.44e-05	0.000228	CcSEcCtD
Oxybutynin—Pruritus—Hydrocortisone—psoriasis	7.43e-05	0.000227	CcSEcCtD
Oxybutynin—Ill-defined disorder—Methotrexate—psoriasis	7.42e-05	0.000227	CcSEcCtD
Oxybutynin—Headache—Cyclosporine—psoriasis	7.4e-05	0.000226	CcSEcCtD
Oxybutynin—Feeling abnormal—Betamethasone—psoriasis	7.39e-05	0.000226	CcSEcCtD
Oxybutynin—Feeling abnormal—Dexamethasone—psoriasis	7.39e-05	0.000226	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Dexamethasone—psoriasis	7.33e-05	0.000224	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Betamethasone—psoriasis	7.33e-05	0.000224	CcSEcCtD
Oxybutynin—Vomiting—Mycophenolate mofetil—psoriasis	7.33e-05	0.000224	CcSEcCtD
Oxybutynin—Hypersensitivity—Triamcinolone—psoriasis	7.28e-05	0.000223	CcSEcCtD
Oxybutynin—Rash—Mycophenolate mofetil—psoriasis	7.27e-05	0.000222	CcSEcCtD
Oxybutynin—Dermatitis—Mycophenolate mofetil—psoriasis	7.26e-05	0.000222	CcSEcCtD
Oxybutynin—Headache—Mycophenolate mofetil—psoriasis	7.22e-05	0.000221	CcSEcCtD
Oxybutynin—Malaise—Methotrexate—psoriasis	7.21e-05	0.000221	CcSEcCtD
Oxybutynin—Diarrhoea—Hydrocortisone—psoriasis	7.18e-05	0.00022	CcSEcCtD
Oxybutynin—CYP3A5—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	7.17e-05	0.0189	CbGpPWpGaD
Oxybutynin—Urticaria—Dexamethasone—psoriasis	7.13e-05	0.000218	CcSEcCtD
Oxybutynin—Urticaria—Betamethasone—psoriasis	7.13e-05	0.000218	CcSEcCtD
Oxybutynin—Musculoskeletal discomfort—Prednisone—psoriasis	7.12e-05	0.000218	CcSEcCtD
Oxybutynin—Dizziness—Prednisolone—psoriasis	7.11e-05	0.000217	CcSEcCtD
Oxybutynin—Asthenia—Triamcinolone—psoriasis	7.09e-05	0.000217	CcSEcCtD
Oxybutynin—Abdominal pain—Betamethasone—psoriasis	7.09e-05	0.000217	CcSEcCtD
Oxybutynin—Abdominal pain—Dexamethasone—psoriasis	7.09e-05	0.000217	CcSEcCtD
Oxybutynin—Insomnia—Prednisone—psoriasis	7.07e-05	0.000216	CcSEcCtD
Oxybutynin—Nausea—Cyclosporine—psoriasis	7.02e-05	0.000215	CcSEcCtD
Oxybutynin—Paraesthesia—Prednisone—psoriasis	7.01e-05	0.000215	CcSEcCtD
Oxybutynin—Pruritus—Triamcinolone—psoriasis	6.99e-05	0.000214	CcSEcCtD
Oxybutynin—Cough—Methotrexate—psoriasis	6.98e-05	0.000214	CcSEcCtD
Oxybutynin—Dizziness—Hydrocortisone—psoriasis	6.94e-05	0.000212	CcSEcCtD
Oxybutynin—Convulsion—Methotrexate—psoriasis	6.93e-05	0.000212	CcSEcCtD
Oxybutynin—Dyspepsia—Prednisone—psoriasis	6.88e-05	0.00021	CcSEcCtD
Oxybutynin—Nausea—Mycophenolate mofetil—psoriasis	6.85e-05	0.000209	CcSEcCtD
Oxybutynin—Arthralgia—Methotrexate—psoriasis	6.81e-05	0.000208	CcSEcCtD
Oxybutynin—Chest pain—Methotrexate—psoriasis	6.81e-05	0.000208	CcSEcCtD
Oxybutynin—Decreased appetite—Prednisone—psoriasis	6.79e-05	0.000208	CcSEcCtD
Oxybutynin—Rash—Prednisolone—psoriasis	6.78e-05	0.000207	CcSEcCtD
Oxybutynin—Dermatitis—Prednisolone—psoriasis	6.77e-05	0.000207	CcSEcCtD
Oxybutynin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	6.76e-05	0.000207	CcSEcCtD
Oxybutynin—Fatigue—Prednisone—psoriasis	6.73e-05	0.000206	CcSEcCtD
Oxybutynin—Headache—Prednisolone—psoriasis	6.73e-05	0.000206	CcSEcCtD
Oxybutynin—Discomfort—Methotrexate—psoriasis	6.73e-05	0.000206	CcSEcCtD
Oxybutynin—Constipation—Prednisone—psoriasis	6.68e-05	0.000204	CcSEcCtD
Oxybutynin—Vomiting—Hydrocortisone—psoriasis	6.68e-05	0.000204	CcSEcCtD
Oxybutynin—Rash—Hydrocortisone—psoriasis	6.62e-05	0.000203	CcSEcCtD
Oxybutynin—Dermatitis—Hydrocortisone—psoriasis	6.61e-05	0.000202	CcSEcCtD
Oxybutynin—Confusional state—Methotrexate—psoriasis	6.58e-05	0.000201	CcSEcCtD
Oxybutynin—Headache—Hydrocortisone—psoriasis	6.58e-05	0.000201	CcSEcCtD
Oxybutynin—Dizziness—Triamcinolone—psoriasis	6.54e-05	0.0002	CcSEcCtD
Oxybutynin—Anaphylactic shock—Methotrexate—psoriasis	6.53e-05	0.0002	CcSEcCtD
Oxybutynin—Infection—Methotrexate—psoriasis	6.49e-05	0.000198	CcSEcCtD
Oxybutynin—Feeling abnormal—Prednisone—psoriasis	6.44e-05	0.000197	CcSEcCtD
Oxybutynin—Asthenia—Betamethasone—psoriasis	6.44e-05	0.000197	CcSEcCtD
Oxybutynin—Asthenia—Dexamethasone—psoriasis	6.44e-05	0.000197	CcSEcCtD
Oxybutynin—Nervous system disorder—Methotrexate—psoriasis	6.4e-05	0.000196	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Prednisone—psoriasis	6.39e-05	0.000195	CcSEcCtD
Oxybutynin—Nausea—Prednisolone—psoriasis	6.39e-05	0.000195	CcSEcCtD
Oxybutynin—Pruritus—Betamethasone—psoriasis	6.35e-05	0.000194	CcSEcCtD
Oxybutynin—Pruritus—Dexamethasone—psoriasis	6.35e-05	0.000194	CcSEcCtD
Oxybutynin—Skin disorder—Methotrexate—psoriasis	6.34e-05	0.000194	CcSEcCtD
Oxybutynin—Vomiting—Triamcinolone—psoriasis	6.29e-05	0.000192	CcSEcCtD
Oxybutynin—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	6.29e-05	0.0166	CbGpPWpGaD
Oxybutynin—Nausea—Hydrocortisone—psoriasis	6.24e-05	0.000191	CcSEcCtD
Oxybutynin—Rash—Triamcinolone—psoriasis	6.23e-05	0.000191	CcSEcCtD
Oxybutynin—Dermatitis—Triamcinolone—psoriasis	6.23e-05	0.000191	CcSEcCtD
Oxybutynin—Anorexia—Methotrexate—psoriasis	6.22e-05	0.00019	CcSEcCtD
Oxybutynin—CYP2C8—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	6.21e-05	0.0164	CbGpPWpGaD
Oxybutynin—Urticaria—Prednisone—psoriasis	6.21e-05	0.00019	CcSEcCtD
Oxybutynin—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	6.2e-05	0.0164	CbGpPWpGaD
Oxybutynin—Headache—Triamcinolone—psoriasis	6.19e-05	0.000189	CcSEcCtD
Oxybutynin—Abdominal pain—Prednisone—psoriasis	6.18e-05	0.000189	CcSEcCtD
Oxybutynin—Diarrhoea—Dexamethasone—psoriasis	6.14e-05	0.000188	CcSEcCtD
Oxybutynin—Diarrhoea—Betamethasone—psoriasis	6.14e-05	0.000188	CcSEcCtD
Oxybutynin—Hypotension—Methotrexate—psoriasis	6.1e-05	0.000187	CcSEcCtD
Oxybutynin—CHRM5—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	6.06e-05	0.016	CbGpPWpGaD
Oxybutynin—Musculoskeletal discomfort—Methotrexate—psoriasis	5.95e-05	0.000182	CcSEcCtD
Oxybutynin—Dizziness—Dexamethasone—psoriasis	5.93e-05	0.000181	CcSEcCtD
Oxybutynin—Dizziness—Betamethasone—psoriasis	5.93e-05	0.000181	CcSEcCtD
Oxybutynin—Insomnia—Methotrexate—psoriasis	5.9e-05	0.000181	CcSEcCtD
Oxybutynin—Nausea—Triamcinolone—psoriasis	5.87e-05	0.00018	CcSEcCtD
Oxybutynin—Paraesthesia—Methotrexate—psoriasis	5.86e-05	0.000179	CcSEcCtD
Oxybutynin—Somnolence—Methotrexate—psoriasis	5.8e-05	0.000178	CcSEcCtD
Oxybutynin—Hypersensitivity—Prednisone—psoriasis	5.76e-05	0.000176	CcSEcCtD
Oxybutynin—Dyspepsia—Methotrexate—psoriasis	5.75e-05	0.000176	CcSEcCtD
Oxybutynin—Vomiting—Dexamethasone—psoriasis	5.7e-05	0.000174	CcSEcCtD
Oxybutynin—Vomiting—Betamethasone—psoriasis	5.7e-05	0.000174	CcSEcCtD
Oxybutynin—Decreased appetite—Methotrexate—psoriasis	5.68e-05	0.000174	CcSEcCtD
Oxybutynin—Rash—Dexamethasone—psoriasis	5.66e-05	0.000173	CcSEcCtD
Oxybutynin—Rash—Betamethasone—psoriasis	5.66e-05	0.000173	CcSEcCtD
Oxybutynin—Dermatitis—Dexamethasone—psoriasis	5.65e-05	0.000173	CcSEcCtD
Oxybutynin—Dermatitis—Betamethasone—psoriasis	5.65e-05	0.000173	CcSEcCtD
Oxybutynin—Gastrointestinal disorder—Methotrexate—psoriasis	5.64e-05	0.000172	CcSEcCtD
Oxybutynin—Fatigue—Methotrexate—psoriasis	5.63e-05	0.000172	CcSEcCtD
Oxybutynin—Headache—Dexamethasone—psoriasis	5.62e-05	0.000172	CcSEcCtD
Oxybutynin—Headache—Betamethasone—psoriasis	5.62e-05	0.000172	CcSEcCtD
Oxybutynin—Asthenia—Prednisone—psoriasis	5.6e-05	0.000171	CcSEcCtD
Oxybutynin—Pain—Methotrexate—psoriasis	5.58e-05	0.000171	CcSEcCtD
Oxybutynin—Pruritus—Prednisone—psoriasis	5.53e-05	0.000169	CcSEcCtD
Oxybutynin—Feeling abnormal—Methotrexate—psoriasis	5.38e-05	0.000165	CcSEcCtD
Oxybutynin—Diarrhoea—Prednisone—psoriasis	5.34e-05	0.000164	CcSEcCtD
Oxybutynin—Gastrointestinal pain—Methotrexate—psoriasis	5.34e-05	0.000163	CcSEcCtD
Oxybutynin—Nausea—Dexamethasone—psoriasis	5.33e-05	0.000163	CcSEcCtD
Oxybutynin—Nausea—Betamethasone—psoriasis	5.33e-05	0.000163	CcSEcCtD
Oxybutynin—Urticaria—Methotrexate—psoriasis	5.19e-05	0.000159	CcSEcCtD
Oxybutynin—Dizziness—Prednisone—psoriasis	5.17e-05	0.000158	CcSEcCtD
Oxybutynin—Abdominal pain—Methotrexate—psoriasis	5.16e-05	0.000158	CcSEcCtD
Oxybutynin—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	5.1e-05	0.0135	CbGpPWpGaD
Oxybutynin—Vomiting—Prednisone—psoriasis	4.97e-05	0.000152	CcSEcCtD
Oxybutynin—Rash—Prednisone—psoriasis	4.93e-05	0.000151	CcSEcCtD
Oxybutynin—Dermatitis—Prednisone—psoriasis	4.92e-05	0.000151	CcSEcCtD
Oxybutynin—Headache—Prednisone—psoriasis	4.89e-05	0.00015	CcSEcCtD
Oxybutynin—Hypersensitivity—Methotrexate—psoriasis	4.81e-05	0.000147	CcSEcCtD
Oxybutynin—Asthenia—Methotrexate—psoriasis	4.68e-05	0.000143	CcSEcCtD
Oxybutynin—Nausea—Prednisone—psoriasis	4.64e-05	0.000142	CcSEcCtD
Oxybutynin—Pruritus—Methotrexate—psoriasis	4.62e-05	0.000141	CcSEcCtD
Oxybutynin—Diarrhoea—Methotrexate—psoriasis	4.47e-05	0.000137	CcSEcCtD
Oxybutynin—CHRM5—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	4.42e-05	0.0117	CbGpPWpGaD
Oxybutynin—Dizziness—Methotrexate—psoriasis	4.32e-05	0.000132	CcSEcCtD
Oxybutynin—CHRM1—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	4.27e-05	0.0113	CbGpPWpGaD
Oxybutynin—CHRM3—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	4.26e-05	0.0112	CbGpPWpGaD
Oxybutynin—CHRM2—Calcium Regulation in the Cardiac Cell—GJB2—psoriasis	4.21e-05	0.0111	CbGpPWpGaD
Oxybutynin—Vomiting—Methotrexate—psoriasis	4.15e-05	0.000127	CcSEcCtD
Oxybutynin—Rash—Methotrexate—psoriasis	4.12e-05	0.000126	CcSEcCtD
Oxybutynin—Dermatitis—Methotrexate—psoriasis	4.11e-05	0.000126	CcSEcCtD
Oxybutynin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	4.11e-05	0.0109	CbGpPWpGaD
Oxybutynin—Headache—Methotrexate—psoriasis	4.09e-05	0.000125	CcSEcCtD
Oxybutynin—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	4.06e-05	0.0107	CbGpPWpGaD
Oxybutynin—Nausea—Methotrexate—psoriasis	3.88e-05	0.000119	CcSEcCtD
Oxybutynin—CHRM2—G alpha (i) signalling events—HCAR2—psoriasis	3.86e-05	0.0102	CbGpPWpGaD
Oxybutynin—CYP3A5—Biological oxidations—CYP2S1—psoriasis	3.81e-05	0.0101	CbGpPWpGaD
Oxybutynin—CYP3A5—Metapathway biotransformation—CYP2S1—psoriasis	3.75e-05	0.00991	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR ligand binding—HCAR2—psoriasis	3.36e-05	0.00888	CbGpPWpGaD
Oxybutynin—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	3.33e-05	0.0088	CbGpPWpGaD
Oxybutynin—CYP2C8—Biological oxidations—CYP2S1—psoriasis	3.3e-05	0.00871	CbGpPWpGaD
Oxybutynin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	3.29e-05	0.00868	CbGpPWpGaD
Oxybutynin—CYP2C8—Metapathway biotransformation—CYP2S1—psoriasis	3.25e-05	0.00859	CbGpPWpGaD
Oxybutynin—CHRM1—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	3.11e-05	0.00821	CbGpPWpGaD
Oxybutynin—CHRM3—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	3.1e-05	0.00819	CbGpPWpGaD
Oxybutynin—CHRM2—Class A/1 (Rhodopsin-like receptors)—HCAR2—psoriasis	3.07e-05	0.00811	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—RUNX3—psoriasis	2.78e-05	0.00735	CbGpPWpGaD
Oxybutynin—CYP2D6—Biological oxidations—CYP2S1—psoriasis	2.71e-05	0.00715	CbGpPWpGaD
Oxybutynin—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	2.67e-05	0.00705	CbGpPWpGaD
Oxybutynin—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	2.62e-05	0.00693	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR ligand binding—HCAR2—psoriasis	2.37e-05	0.00625	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR ligand binding—HCAR2—psoriasis	2.36e-05	0.00623	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR ligand binding—HCAR2—psoriasis	2.34e-05	0.00617	CbGpPWpGaD
Oxybutynin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	2.29e-05	0.00606	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—IL13—psoriasis	2.2e-05	0.0058	CbGpPWpGaD
Oxybutynin—CHRM2—G alpha (i) signalling events—CCL20—psoriasis	2.01e-05	0.0053	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—HCAR2—psoriasis	1.9e-05	0.00502	CbGpPWpGaD
Oxybutynin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	1.89e-05	0.00498	CbGpPWpGaD
Oxybutynin—CYP3A4—Biological oxidations—CYP2S1—psoriasis	1.77e-05	0.00467	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR ligand binding—CCL20—psoriasis	1.75e-05	0.00461	CbGpPWpGaD
Oxybutynin—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	1.75e-05	0.00461	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—HCAR2—psoriasis	1.73e-05	0.00456	CbGpPWpGaD
Oxybutynin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	1.62e-05	0.00427	CbGpPWpGaD
Oxybutynin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	1.61e-05	0.00425	CbGpPWpGaD
Oxybutynin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	1.59e-05	0.00421	CbGpPWpGaD
Oxybutynin—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	1.56e-05	0.00412	CbGpPWpGaD
Oxybutynin—CYP3A4—Tryptophan metabolism—CAT—psoriasis	1.53e-05	0.00403	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—IL10—psoriasis	1.37e-05	0.00363	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—HCAR2—psoriasis	1.34e-05	0.00353	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—HCAR2—psoriasis	1.33e-05	0.00352	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—HCAR2—psoriasis	1.32e-05	0.00349	CbGpPWpGaD
Oxybutynin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.32e-05	0.00347	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR ligand binding—CCL20—psoriasis	1.23e-05	0.00325	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR ligand binding—CCL20—psoriasis	1.23e-05	0.00324	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—HCAR2—psoriasis	1.22e-05	0.00321	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR ligand binding—CCL20—psoriasis	1.21e-05	0.00321	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—HCAR2—psoriasis	1.21e-05	0.0032	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—HCAR2—psoriasis	1.2e-05	0.00317	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—HCAR2—psoriasis	1.02e-05	0.00269	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—CCL20—psoriasis	9.87e-06	0.00261	CbGpPWpGaD
Oxybutynin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	9.61e-06	0.00254	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—LEP—psoriasis	9.36e-06	0.00247	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—NDUFA5—psoriasis	9.1e-06	0.0024	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—CCL20—psoriasis	8.97e-06	0.00237	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—TAGAP—psoriasis	8.84e-06	0.00233	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—NOS2—psoriasis	8.72e-06	0.0023	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—PPARG—psoriasis	8.15e-06	0.00215	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—CYP2S1—psoriasis	7.74e-06	0.00204	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—NDUFA5—psoriasis	7.66e-06	0.00202	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.52e-06	0.00199	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—HCAR2—psoriasis	7.18e-06	0.0019	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—HCAR2—psoriasis	7.16e-06	0.00189	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—HCAR2—psoriasis	7.09e-06	0.00187	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—JUN—psoriasis	6.99e-06	0.00185	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—CCL20—psoriasis	6.95e-06	0.00184	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—CCL20—psoriasis	6.93e-06	0.00183	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—CCL20—psoriasis	6.86e-06	0.00181	CbGpPWpGaD
Oxybutynin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.77e-06	0.00179	CbGpPWpGaD
Oxybutynin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	6.75e-06	0.00178	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.73e-06	0.00178	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—NDUFA5—psoriasis	6.63e-06	0.00175	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—CYP2S1—psoriasis	6.51e-06	0.00172	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—CCL20—psoriasis	6.31e-06	0.00167	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—CCL20—psoriasis	6.29e-06	0.00166	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—CCL20—psoriasis	6.23e-06	0.00165	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—TAGAP—psoriasis	6.23e-06	0.00164	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—TAGAP—psoriasis	6.21e-06	0.00164	CbGpPWpGaD
Oxybutynin—CHRM5—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	6.2e-06	0.00164	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	6.18e-06	0.00163	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—TAGAP—psoriasis	6.15e-06	0.00162	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—VEGFA—psoriasis	6.11e-06	0.00161	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—JUN—psoriasis	5.78e-06	0.00153	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—CYP2S1—psoriasis	5.64e-06	0.00149	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—NDUFA5—psoriasis	5.44e-06	0.00144	CbGpPWpGaD
Oxybutynin—CHRM2—G alpha (i) signalling events—CXCL8—psoriasis	5.42e-06	0.00143	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—CCL20—psoriasis	5.3e-06	0.0014	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—TNF—psoriasis	5.23e-06	0.00138	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR ligand binding—CXCL8—psoriasis	4.72e-06	0.00125	CbGpPWpGaD
Oxybutynin—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.7e-06	0.00124	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—CYP2S1—psoriasis	4.63e-06	0.00122	CbGpPWpGaD
Oxybutynin—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.36e-06	0.00115	CbGpPWpGaD
Oxybutynin—CHRM3—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.35e-06	0.00115	CbGpPWpGaD
Oxybutynin—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.31e-06	0.00114	CbGpPWpGaD
Oxybutynin—CHRM2—SIDS Susceptibility Pathways—IL6—psoriasis	4.22e-06	0.00112	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—TP53—psoriasis	3.82e-06	0.00101	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—CARM1—psoriasis	3.78e-06	0.000998	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—CCL20—psoriasis	3.73e-06	0.000985	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—CCL20—psoriasis	3.72e-06	0.000982	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—CCL20—psoriasis	3.68e-06	0.000972	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—NDUFA5—psoriasis	3.56e-06	0.00094	CbGpPWpGaD
Oxybutynin—CHRM1—Circadian rythm related genes—IL6—psoriasis	3.49e-06	0.000922	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR ligand binding—CXCL8—psoriasis	3.32e-06	0.000877	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR ligand binding—CXCL8—psoriasis	3.31e-06	0.000874	CbGpPWpGaD
Oxybutynin—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.31e-06	0.000874	CbGpPWpGaD
Oxybutynin—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	3.3e-06	0.000871	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR ligand binding—CXCL8—psoriasis	3.28e-06	0.000866	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—CARM1—psoriasis	3.18e-06	0.000839	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—CYP2S1—psoriasis	3.03e-06	0.000799	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.95e-06	0.00078	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—SOCS1—psoriasis	2.92e-06	0.00077	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—TYK2—psoriasis	2.78e-06	0.000734	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—CARM1—psoriasis	2.75e-06	0.000727	CbGpPWpGaD
Oxybutynin—CHRM5—GPCR downstream signaling—CXCL8—psoriasis	2.67e-06	0.000704	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.57e-06	0.00068	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—CXCL8—psoriasis	2.42e-06	0.000639	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—CAT—psoriasis	2.33e-06	0.000614	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—CARM1—psoriasis	2.26e-06	0.000597	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—APOE—psoriasis	2.15e-06	0.000568	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—LEP—psoriasis	2.15e-06	0.000568	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—SOCS1—psoriasis	2.05e-06	0.000542	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—SOCS1—psoriasis	2.05e-06	0.000541	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—SOCS1—psoriasis	2.03e-06	0.000535	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—NFKBIA—psoriasis	2.01e-06	0.00053	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—TYK2—psoriasis	1.96e-06	0.000517	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—CAT—psoriasis	1.96e-06	0.000516	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—TYK2—psoriasis	1.95e-06	0.000515	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—TYK2—psoriasis	1.93e-06	0.00051	CbGpPWpGaD
Oxybutynin—CHRM1—GPCR downstream signaling—CXCL8—psoriasis	1.88e-06	0.000496	CbGpPWpGaD
Oxybutynin—CHRM3—GPCR downstream signaling—CXCL8—psoriasis	1.87e-06	0.000494	CbGpPWpGaD
Oxybutynin—CHRM2—GPCR downstream signaling—CXCL8—psoriasis	1.85e-06	0.000489	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—APOE—psoriasis	1.81e-06	0.000477	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—CXCL8—psoriasis	1.7e-06	0.00045	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—CXCL8—psoriasis	1.7e-06	0.000449	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—CAT—psoriasis	1.69e-06	0.000447	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—CXCL8—psoriasis	1.68e-06	0.000444	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—TYK2—psoriasis	1.64e-06	0.000434	CbGpPWpGaD
Oxybutynin—CHRM3—Metabolism—PPARG—psoriasis	1.57e-06	0.000416	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—APOE—psoriasis	1.52e-06	0.000401	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—LEP—psoriasis	1.52e-06	0.0004	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—APOE—psoriasis	1.52e-06	0.0004	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—LEP—psoriasis	1.51e-06	0.000399	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—APOE—psoriasis	1.51e-06	0.000399	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—LEP—psoriasis	1.5e-06	0.000395	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—APOE—psoriasis	1.5e-06	0.000395	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—CARM1—psoriasis	1.48e-06	0.00039	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—CXCL8—psoriasis	1.43e-06	0.000378	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—NFKBIA—psoriasis	1.41e-06	0.000373	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—NFKBIA—psoriasis	1.41e-06	0.000372	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—NFKBIA—psoriasis	1.39e-06	0.000368	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—CAT—psoriasis	1.39e-06	0.000367	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling by GPCR—IL6—psoriasis	1.36e-06	0.000359	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—JUN—psoriasis	1.33e-06	0.000351	CbGpPWpGaD
Oxybutynin—CYP3A5—Metabolism—PPARG—psoriasis	1.32e-06	0.000349	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—APOE—psoriasis	1.32e-06	0.000347	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—NFKB1—psoriasis	1.28e-06	0.000338	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—VEGFA—psoriasis	1.16e-06	0.000307	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—TYK2—psoriasis	1.16e-06	0.000305	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—TYK2—psoriasis	1.15e-06	0.000304	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—STAT3—psoriasis	1.15e-06	0.000304	CbGpPWpGaD
Oxybutynin—CYP2C8—Metabolism—PPARG—psoriasis	1.15e-06	0.000303	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—TYK2—psoriasis	1.14e-06	0.000302	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—APOE—psoriasis	1.08e-06	0.000285	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—CXCL8—psoriasis	1.01e-06	0.000266	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—CXCL8—psoriasis	1e-06	0.000265	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—CXCL8—psoriasis	9.94e-07	0.000263	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling by GPCR—IL6—psoriasis	9.58e-07	0.000253	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling by GPCR—IL6—psoriasis	9.55e-07	0.000252	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling by GPCR—IL6—psoriasis	9.45e-07	0.00025	CbGpPWpGaD
Oxybutynin—CYP2D6—Metabolism—PPARG—psoriasis	9.41e-07	0.000248	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—JUN—psoriasis	9.36e-07	0.000247	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—JUN—psoriasis	9.33e-07	0.000246	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—JUN—psoriasis	9.24e-07	0.000244	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—CAT—psoriasis	9.09e-07	0.00024	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—NFKB1—psoriasis	9.01e-07	0.000238	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—NFKB1—psoriasis	8.98e-07	0.000237	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—NFKB1—psoriasis	8.9e-07	0.000235	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—TP53—psoriasis	8.78e-07	0.000232	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—VEGFA—psoriasis	8.18e-07	0.000216	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—VEGFA—psoriasis	8.15e-07	0.000215	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—STAT3—psoriasis	8.1e-07	0.000214	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—VEGFA—psoriasis	8.07e-07	0.000213	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—STAT3—psoriasis	8.07e-07	0.000213	CbGpPWpGaD
Oxybutynin—CHRM5—Signaling Pathways—IL6—psoriasis	8.04e-07	0.000212	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—STAT3—psoriasis	8e-07	0.000211	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—APOE—psoriasis	7.06e-07	0.000187	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—TP53—psoriasis	6.18e-07	0.000163	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—TP53—psoriasis	6.16e-07	0.000163	CbGpPWpGaD
Oxybutynin—CYP3A4—Metabolism—PPARG—psoriasis	6.15e-07	0.000162	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—TP53—psoriasis	6.1e-07	0.000161	CbGpPWpGaD
Oxybutynin—CHRM1—Signaling Pathways—IL6—psoriasis	5.66e-07	0.000149	CbGpPWpGaD
Oxybutynin—CHRM3—Signaling Pathways—IL6—psoriasis	5.64e-07	0.000149	CbGpPWpGaD
Oxybutynin—CHRM2—Signaling Pathways—IL6—psoriasis	5.58e-07	0.000147	CbGpPWpGaD
